Inhibitors to clotting factors

Annals of Hematology

Volumn 75, Issue 1-2, 1997, Pages 1-7

  Sallah, S ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Antiphospholipid antibodies; Bleeding; Coagulation factors; Inhibitor; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALLOANTIBODY; ANTITHROMBIN III; AUTOANTIBODY; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; FIBRIN; FIBRINOGEN; HEPARIN; NEUTRALIZING ANTIBODY; PHOSPHOLIPID ANTIBODY; PLASMA PROTEIN; PREDNISONE; PROTEIN C; PROTEIN S; WARFARIN;

ANTIBODY PRODUCTION; ARTERY THROMBOSIS; AUTOIMMUNITY; BLEEDING DISORDER; BLEEDING TENDENCY; BLOOD CLOTTING; BLOOD CLOTTING FACTOR DEFICIENCY; CLINICAL FEATURE; DRUG THERAPY; ETIOLOGY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; VEIN THROMBOSIS;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BLOOD COAGULATION FACTORS; DRUG HYPERSENSITIVITY; ENZYME ACTIVATION; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGIC DISORDERS; HUMANS; ISOANTIBODIES; LUPUS COAGULATION INHIBITOR; MALE; MIDDLE AGED; NEOPLASMS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

EID: 0030815001     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050305     Document Type: Review

References (47)

1. Hoyer LW (1995) The incidence of factor VIII inhibitors in patients with severe hemophilia A. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC (eds) Inhibitors to coagulation factors. Plenum, Chapel Hill, pp 35-46
2. Hoyer LW (1995) Factor VIII inhibitors. Curr Opin Hematol 2:365-371
3. Lakich D, Kazazian HH, Antonarakis SE, Gitshier J (1993) Inversions disrupting the factor VIII gene are a common cause of severe hemophilia A. Nature Genet 5:236-241
4. Antonarakis SE, Kazzazian HH, Tuddenham EGD (1994) Molecular etiology of factor VIII deficiency in hemophilia A. Hum Mutation 5:1-22
5. McMillan CW, Shapiro SS, Whitehursr D, et al (1988) The natural history of factor VIII inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII C inhibitors. Blood 71:344-348
6. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al (1993) A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 81:2180-2184
7. Peerlink K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J (1993) A higher than expected incidence of factor VIII inhibitors in multitransfused hemophilia A patients treated with an intermediate purity paturized factor VIII concentrate. Thromb Haemost 69:115-118
8. Bray GL, Gomperts ED, Courter S, et al, and the recombinate study group (1994) A multicenter study of recombinant factor VIII [recombinate]: Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 83:2428-2435
9. Green D, Lechner K (1981) A survey of 215 non-henophilic patients with inhibitors to factor VIII. Thromb Haemost 45:200-203
10. Hutlin MB 91994) Acquired inhibitors in malignant and non malignant disease states. Am J Med 91 [Suppl]:9-13
11. Fulcher CA, de Graaf MS, Zimmerman TS (1987) Factor VIII inhibitor IgG subclass and factor VIII polypeptide specificity determined by immunoblotting. Blood 69:1475-1480
12. Hoyer LW, Gawryl G, De la Fuente B (1984) Immunochemical characterization of VIII inhibitors. Prog Clin Biol Res 150:73-85
13. Clyne LP, White PF (1988) Time dependency of lupus-like anticoagulants. Arch Int Med 148, 1068-1083
14. Kasper CK (1991) Complications of hemophilia A treatment: factor VIII inhibitors. Ann New York Acad Sci 614:97-105
15. Scandella D, Gilbert GE, et al (1995) Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain in amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 85:1811-1819
16. Kasper CK (1991) Lab tests for factor VIII inhibitors; their variation, significance and interpretation. Blood Coagul Fibrinolysis 2 [Suppl 1]:7-10
17. Kasper CK, Aledort LM, Counts RB, et al (1975) A more uniform measurement of factor VIII inhibitors. Throm Diath Haemorrh 34:875-876
18. Roberts HR, Sallah S (1996) Immunology of inhibitors to clotting factors with emphasis on factor VIII. In: Silberstein LE (ed) Autoimmune disorders of blood. American Association of Blood Banks, Bethesda, Maryland, pp 151-170
19. Kernoff PBA (1991) Rationale and evolution of therapy with porcine factor VIII:C. Am J Med 91 [Suppl]:20-22
20. Lusher JM (1984) The role of prothrombin complex concentrates in the treatment of hemophiliacs with factor VIII antibodies. Scand J Haematol [Suppl] 40:195-202
21. Hilgartner MW, Knatterud GL, and the FEIBA study group [1983] The use of factor VIII inhibitor by-passing activity (FEIBA IMMUNO) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 61:36-40
22. Hedner U (1990) Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1:307-310
23. Slocombe GW, Newland AC, Calvin MP, Calvin BT (1981) The role of intensive plasma exchange in the prevention and management of hemorrhage in patients with inhibitors to factor VIII. Br J Haematol 47:577-585
24. Ehrenforth S, Kreuz W, Scharrer I, et al (1992) Incidence of development of factor VIII and factor IX inhibitors in hemophiliacs. Lancet 339:594-598
25. Nilsson IM, Hedner U, Bjorlin B (1973) Suppression of factor IX by cyclophosphamide. Ann Intern Med 78:91-95
26. Glaspy JA (1992) Hemostatic abnormalities in multiple myeloma and related disorders. Hematology-Oncology Clinics of North America 6:1301-1314
27. Feinstein DI (1978) Acquired inhibitors of factor V. Thromb Haemost 39:663-674
28. Budde U, Schaefer G, Mueller N, et al (1984) Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 64:981-985
29. Bentrop E, Nilsson IM (1989) Use of high-purity factor VIII concentrate (Humate-P) in von Willebrand disease. Vox Sang 56:212-217
30. Roubey RAS (1994) Autoantibodies to phospholipid-binding plasma proteins. A new view of lupus anticoagulants and other antiphospholipid autoantibodies. Blood 84:2854-2867
31. Vermylen J, Arnout J (1992) Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes? J Lab Clin Med 120:10-12
32. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF (1991) Lupus anticoagulant (LA) IgGs are not directed to phospholipids only but to a complex of lipid-bound prothrombin. Thromb Haemost 66:629-632
33. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA (1990) Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2 glycoprotein I (apoliproprotein H). Proc Natl Acad Sci USA 87:4120-4124
34. Matsuura E, Igarashi M, Igarashi Y, et al (1995) Molecular aspects of phospholipid binding sites and cryptic epitopes appearing on beta 2 glycoprotein I structure recognized by anticardiolipin antibodies. Lupus 4:S13-S15
35. Baudo F, Redaelli R, Pezzetti L, et al (1990) Prothrombinantibody consistent with lupus anticoagulant. Clinical study and immunochemical characterization. Thromb Res 57:279-287
36. Ruiz-Arguelles A, Vasques-Prado J, Deleze M, et al (1993) Presence of serum antibodies to coagulation protein C in patients with systemic lupus erythematosus is not associated with antigenic or functional protein C deficiencies. Am J Hematol 44:58-59
37. Oosting JD, Derksen RHWM, Bobbick IWG, et al (1993) Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, protein S: an explanation for their pathogenic mechanism. Blood 2618-2625
38. Alarcon-Segovia D (1992) Clinical manifestations of the antiphospholipid antibody syndrome. J Rheumatol 19:1778-1781
39. Long AA, Ginsberg JS, Brill-Edwards P, et al (1991) The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 66:520-524
40. Levine SR, Deegan MJ, Futrell N, Welch KMA (1990) Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 40:1181-1189
41. Freyssinet JM, Cazenave JP (1987) Lupus-like anticoagulant. Modulation of the protein C pathway and thrombosis. Thromb Haemost 58:679-681
42. Triplett DA (1995) Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 78:1-31
43. Exner T, Triplett DA, Taberner D, Machin SJ (1991) Guidelines for testing and revised criteria for lupus anticoagulant: SSC subcommittee for standardization of lupus anticoagulants. Thromb Haemost 65:320-322
44. Derksen RHWM, de Groot PG, Kater L, Niewenhuis HK, et al (1993) Patients with antiphospholipid antibodies and venous thrombosis should receive long-term anticoagulant treatment. Ann Rheum Dis 52:689-692
45. Munther A, Khamashta MD, Cuadrado MJ, et al (1995) The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 332:993-997
46. Silveira LH, Hubble CL, Jara LJ, et al (1992) Prevention of anticardiolipin antibody-related pregnancy losses with prednisone and aspirin. Am J Med 93:403-411
47. Rosove MH, Tabesh K, Wasserstrum N, et al (1990) Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol 75:730-734